Navigation Links
Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
Date:8/4/2011

CRANBURY, N.J., Aug. 4, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity. AZD2820 is a clinical candidate selected by AstraZeneca from its collaborative research program with Palatin Technologies.

Obesity is a global problem, with the World Health Organization estimating that over 1.5 billion adults are overweight and over 500 million are obese. Worldwide obesity has more than doubled since 1980.  A number of different metabolic and hormonal pathways are being evaluated by companies around the world in efforts to develop better treatments for obesity. Scientific research has established that melanocortin receptors have a role in eating behavior and energy homeostasis, and that some melanocortin receptor agonists decrease food intake and induce weight loss in animal studies.

The single center study is expected to enroll 90 subjects in a randomized, single-blind, placebo-controlled, Phase 1 trial in healthy male volunteers. For more information on this clinical trial with AZD2820, please visit www.clinicaltrials.gov .

"We are very pleased that AstraZeneca has initiated a Phase 1 clinical trial with a collaboration compound, demonstrating AstraZeneca's ongoing commitment and diligence in exploring melanocortin compounds for the treatment of obesity," said Dr. Carl Spana, President and Chief Executive Officer of Palatin.

Pursuant to the terms of the research collaboration and license agreement with AstraZeneca, Palatin is eligible for milestone payments upon achieving development and regulatory milestones and further payments on achievement of sales targets, in addition to roy
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
2. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
3. Palatin Technologies, Inc. Announces Results of Annual Stockholders Meeting
4. Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference
5. Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
6. Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants
7. Palatin Technologies, Inc. December 31, 2010 Quarter Results; Teleconference and Webcast to be Held on February 24, 2011
8. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2011 Results
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
10. Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
11. Palatin Announces Strategic Realignment of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Island, New York (PRWEB) December 23, 2014 ... and the Long Island Affiliate of ITRA Global, the national ... slow but steady recovery. This is evidenced by the ... the strong stock market. Low energy costs have held ... The only negative is the housing market remaining soft. ...
(Date:12/24/2014)... Nashville, Tenn. (PRWEB) December 23, 2014 ... Hill was elected treasurer for the American Society ... to advancing knowledge and research in reproductive medicine. ... fills a seat on the executive board and will ... , Dr. Hill has actively supported ASRM since ...
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... CHERTSEY, England, Dec. 27, 2011  United Therapeutics Corporation ... subsidiary, United Therapeutics Europe, Ltd., announced today that ... Securite Sanitaire des Produits de Sante (AFSSAPS) ... the treatment of pulmonary arterial hypertension (PAH).  Remodulin ...
... WEST LAFAYETTE, Ind. Researchers have shown ... manipulate light in new ways that could make possible a ... and computers., The researchers ... property of light called its phase. Light is transmitted as ...
... 2011 In recognition of the International Year of Chemistry ... The Changing Role of Chemistry in Drug Discovery . ... with insights from industry experts, the new report forecasts the ... report suggests, a much more targeted, patient-specific approach will define ...
Cached Biology Technology:Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 2Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 3Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 4Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 5'Nanoantennas' show promise in optical innovations 2'Nanoantennas' show promise in optical innovations 3Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era 2Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era 3
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/17/2014)... -- Automation is fundamentally transforming the travel experience and ... borders. Over the past decade, ePassports, biometric readers, ... to self process through border control via eGates ... increasing number of airports, seaports, and land borders ... Maxine Most , Principal at Acuity Market ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... crystallised a protein that may help gut bacteria bind to the ... identify strains that are likely to be of real benefit to ... to have a beneficial effect, and if they attach to surfaces ... enough to exert their activity," says Dr Nathalie Juge from the ...
... College of Medical Toxicology (ACMT) have signed an agreement to ... Toxicology (JMT), the official journal of the ACMT, beginning ... University of Pennsylvania Press. The Journal of ... advancing the science and practice of medical toxicology. The ...
... food is a matter of debate. A high-profile study a ... of their carbon from trees and leaves, evidence for a ... But new research from the University of Washington shows this ... richer diet for fish and other aquatic life, according to ...
Cached Biology News:A sticky solution for identifying effective probiotics 2Springer and the American College of Medical Toxicology to work together 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3
Weinreb Linker...
...
Rabbit polyclonal to M13 Bacteriophage Coat Proteins ( Abpromise for all tested applications)....
Recognizes the 41 and 43 kDa G-proteins present in liver plasma membranes and Gq/11alpha expressed in the Sf9 insect cell expression system. Negative for recombinant G(I)alpha subtypes....
Biology Products: